Cargando…

Arthritis and pain. Future targets to control osteoarthritis pain

Clinical presentation of osteoarthritis (OA) is dominated by pain during joint use and at rest. OA pain is caused by aberrant functioning of a pathologically altered nervous system with key mechanistic drivers from peripheral nerves and central pain pathways. This review focuses on symptomatic pain...

Descripción completa

Detalles Bibliográficos
Autores principales: Dray, Andy, Read, Simon J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206352/
https://www.ncbi.nlm.nih.gov/pubmed/17561993
http://dx.doi.org/10.1186/ar2178
_version_ 1782148451638706176
author Dray, Andy
Read, Simon J
author_facet Dray, Andy
Read, Simon J
author_sort Dray, Andy
collection PubMed
description Clinical presentation of osteoarthritis (OA) is dominated by pain during joint use and at rest. OA pain is caused by aberrant functioning of a pathologically altered nervous system with key mechanistic drivers from peripheral nerves and central pain pathways. This review focuses on symptomatic pain therapy exemplified by molecular targets that alter sensitization and hyperexcitability of the nervous system, for example, opioids and cannabinoids. We highlight opportunities for targeting inflammatory mediators and their key receptors (for example, prostanoids, kinins, cytokines and chemokines), ion channels (for example, NaV1.8, NaV1.7 and CaV2.2) and neurotrophins (for example, nerve growth factor), noting evidence that relates to their participation in OA etiology and treatment. Future neurological treatments of pain appear optimistic but will require the systematic evaluation of emerging opportunities.
format Text
id pubmed-2206352
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-22063522008-01-19 Arthritis and pain. Future targets to control osteoarthritis pain Dray, Andy Read, Simon J Arthritis Res Ther Review Clinical presentation of osteoarthritis (OA) is dominated by pain during joint use and at rest. OA pain is caused by aberrant functioning of a pathologically altered nervous system with key mechanistic drivers from peripheral nerves and central pain pathways. This review focuses on symptomatic pain therapy exemplified by molecular targets that alter sensitization and hyperexcitability of the nervous system, for example, opioids and cannabinoids. We highlight opportunities for targeting inflammatory mediators and their key receptors (for example, prostanoids, kinins, cytokines and chemokines), ion channels (for example, NaV1.8, NaV1.7 and CaV2.2) and neurotrophins (for example, nerve growth factor), noting evidence that relates to their participation in OA etiology and treatment. Future neurological treatments of pain appear optimistic but will require the systematic evaluation of emerging opportunities. BioMed Central 2007 2007-05-30 /pmc/articles/PMC2206352/ /pubmed/17561993 http://dx.doi.org/10.1186/ar2178 Text en Copyright © 2007 BioMed Central Ltd
spellingShingle Review
Dray, Andy
Read, Simon J
Arthritis and pain. Future targets to control osteoarthritis pain
title Arthritis and pain. Future targets to control osteoarthritis pain
title_full Arthritis and pain. Future targets to control osteoarthritis pain
title_fullStr Arthritis and pain. Future targets to control osteoarthritis pain
title_full_unstemmed Arthritis and pain. Future targets to control osteoarthritis pain
title_short Arthritis and pain. Future targets to control osteoarthritis pain
title_sort arthritis and pain. future targets to control osteoarthritis pain
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206352/
https://www.ncbi.nlm.nih.gov/pubmed/17561993
http://dx.doi.org/10.1186/ar2178
work_keys_str_mv AT drayandy arthritisandpainfuturetargetstocontrolosteoarthritispain
AT readsimonj arthritisandpainfuturetargetstocontrolosteoarthritispain